Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2017

Date: November 14, 2017
Pages: 255
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: RA1B2886D56EN
Leaflet:

Download PDF Leaflet

Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2017, provides an overview of the Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline landscape.

Respiratory syncytial virus (RSV) infection is a respiratory disease. It infects the lungs and breathing passages. RSV commonly causes bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children less than one year of age. The symptoms of RSV infection include cough, stuffy or runny nose, mild sore throat, earache and fever. Treatment includes proper medication and hygiene practice.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Respiratory Syncytial Virus (RSV) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 15, 13, 46, 22 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 9, 17 and 6 molecules, respectively.

Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Respiratory Syncytial Virus (RSV) Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Respiratory Syncytial Virus (RSV) Infections - Overview
Respiratory Syncytial Virus (RSV) Infections - Therapeutics Development
Respiratory Syncytial Virus (RSV) Infections - Therapeutics Assessment
Respiratory Syncytial Virus (RSV) Infections - Companies Involved in Therapeutics Development
Respiratory Syncytial Virus (RSV) Infections - Drug Profiles
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects
Respiratory Syncytial Virus (RSV) Infections - Discontinued Products
Respiratory Syncytial Virus (RSV) Infections - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Products under Development by Universities/Institutes, H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by 3-V Biosciences Inc, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Abivax SA, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Ablynx NV, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by ADMA Biologics Inc, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Agilvax Inc, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Amarillo Biosciences Inc, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Anima Biotech Ltd, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Aridis Pharmaceuticals LLC, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Artificial Cell Technologies Inc, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by AstraZeneca Plc, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Aviragen Therapeutics Inc, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Bavarian Nordic A/S, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Celltrion Inc, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Curevac AG, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by DBV Technologies SA, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Enanta Pharmaceuticals Inc, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Evec Inc, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Gene Techno Science Co Ltd, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by GenVec Inc, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Gilead Sciences Inc, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by GlaxoSmithKline Plc, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Globavir Biosciences Inc, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by iBio Inc, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Immunovaccine Inc, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Immunwork Inc, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Inovio Pharmaceuticals Inc, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Johnson & Johnson, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Karyopharm Therapeutics Inc, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Kineta Inc, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by mAbxience SA, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by MedImmune LLC, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Medivir AB, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Merck & Co Inc, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Mucosis BV (Inactive), H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Mymetics Corp, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by NanoBio Corp, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Navigen Inc, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Novavax Inc, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Phoenix Biotechnology Inc, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Profectus BioSciences Inc, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Pulmocide Ltd, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by ReViral Ltd, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Romark Laboratories LC, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Sanofi, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by TechnoVax Inc, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Themis Bioscience GmbH, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Vault Pharma Inc, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Vaxart Inc, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by VBI Vaccines Inc, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Virometix AG, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Visterra Inc, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Pipeline by VLP Biotech Inc, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects, H2 2017
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects, H2 2017 (Contd..1), H2 2017
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects, H2 2017 (Contd..2), H2 2017
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects, H2 2017 (Contd..3), H2 2017
Respiratory Syncytial Virus (RSV) Infections - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

3-V Biosciences Inc
Abivax SA
Ablynx NV
ADMA Biologics Inc
Agilvax Inc
Amarillo Biosciences Inc
Anima Biotech Ltd
Aridis Pharmaceuticals LLC
Artificial Cell Technologies Inc
AstraZeneca Plc
Aviragen Therapeutics Inc
Bavarian Nordic A/S
Celltrion Inc
Curevac AG
DBV Technologies SA
Enanta Pharmaceuticals Inc
Evec Inc
F. Hoffmann-La Roche Ltd
Gene Techno Science Co Ltd
GenVec Inc
Gilead Sciences Inc
GlaxoSmithKline Plc
Globavir Biosciences Inc
iBio Inc
Immunovaccine Inc
Immunwork Inc
Inovio Pharmaceuticals Inc
Johnson & Johnson
Karyopharm Therapeutics Inc
Kineta Inc
mAbxience SA
MedImmune LLC
Medivir AB
Merck & Co Inc
Mucosis BV (Inactive)
Mymetics Corp
NanoBio Corp
Navigen Inc
Novavax Inc
Phoenix Biotechnology Inc
Profectus BioSciences Inc
Pulmocide Ltd
ReViral Ltd
Romark Laboratories LC
Sanofi
Takeda Pharmaceutical Co Ltd
TechnoVax Inc
Themis Bioscience GmbH
Vault Pharma Inc
Vaxart Inc
VBI Vaccines Inc
Virometix AG
Visterra Inc
VLP Biotech Inc
Skip to top


West Nile Virus Infections - Pipeline Review, H2 2017 US$ 2,000.00 Sep, 2017 · 66 pages

Ask Your Question

Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: